GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Cash Flow from Investing

AVANIR Pharmaceuticals (FRA:AV2B) Cash Flow from Investing : €-2.51 Mil (TTM As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2014, AVANIR Pharmaceuticals spent €0.46 Mil on purchasing property, plant, equipment. It gained €0.00 Mil from selling property, plant, and equipment. It spent €0.00 Mil on purchasing business. It gained €0.00 Mil from selling business. It spent €0.00 Mil on purchasing investments. It gained €0.00 Mil from selling investments. It paid €0.00Mil for net Intangibles purchase and sale. And it paid €0.00 Mil for other investing activities. In all, AVANIR Pharmaceuticals spent €0.46 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2014.


AVANIR Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for AVANIR Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Cash Flow from Investing Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -2.53 -0.71 -0.27 -2.64

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 -1.18 -0.70 -0.18 -0.46

AVANIR Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

AVANIR Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Sep. 2014 is calculated as:

AVANIR Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Sep. 2014 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVANIR Pharmaceuticals  (FRA:AV2B) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

AVANIR Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Sep. 2014 was €-0.46 Mil. It means AVANIR Pharmaceuticals spent €0.46 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

AVANIR Pharmaceuticals's sale of property, plant, equipment for the three months ended in Sep. 2014 was €0.00 Mil. It means AVANIR Pharmaceuticals gained €0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

AVANIR Pharmaceuticals's purchase of business for the three months ended in Sep. 2014 was €0.00 Mil. It means AVANIR Pharmaceuticals spent €0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

AVANIR Pharmaceuticals's sale of business for the three months ended in Sep. 2014 was €0.00 Mil. It means AVANIR Pharmaceuticals gained €0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

AVANIR Pharmaceuticals's purchase of investment for the three months ended in Sep. 2014 was €0.00 Mil. It means AVANIR Pharmaceuticals spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

AVANIR Pharmaceuticals's sale of investment for the three months ended in Sep. 2014 was €0.00 Mil. It means AVANIR Pharmaceuticals gained €0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

AVANIR Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Sep. 2014 was €0.00 Mil. It means AVANIR Pharmaceuticals paid €0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

AVANIR Pharmaceuticals's cash from discontinued investing activities for the three months ended in Sep. 2014 was 0.00 Mil. It means AVANIR Pharmaceuticals paid €0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

AVANIR Pharmaceuticals's cash from other investing activities for the three months ended in Sep. 2014 was €0.00 Mil. It means AVANIR Pharmaceuticals paid €0.00 Mil for other investing activities.


AVANIR Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines